# AI Biotechnology LLC — merger [announced]
Source: SEC API (secapi.ai) · situation sit_1de297b157970035cedf · retrieved 2026-08-11T16:11:26.279Z

## Overview
Yarrow Bioscience, Inc. (formerly VYNE Therapeutics Inc.) is a pharmaceutical preparations company.

On July 27, 2026, Yellow Merger Sub Corp., a wholly owned subsidiary of VYNE Therapeutics Inc., merged with and into Yarrow Bioscience, Inc. (Pre-Merger Yarrow), with Pre-Merger Yarrow continuing as a wholly owned subsidiary of VYNE Therapeutics Inc. and serving as the surviving corporation. In connection with the merger's completion, VYNE Therapeutics Inc. changed its name to Yarrow Bioscience, Inc. Prior to the merger, the company effected a 1-for-50 reverse stock split effective July 24, 2026, under which every 50 shares of Common Stock were automatically combined into one share. As a result of the reverse stock split, AI Biotechnology's 1,116,585 shares were combined into 22,331 whole shares, and the Warrants held by AI Biotechnology were adjusted from 7,792,448 shares to 155,849 shares issuable upon exercise.

## Terms
- Counterparty: Yarrow Bioscience, Inc. · Stake: 6.02%

## Key dates
- Announced 2026-07-29

## Timeline
- 2026-07-29 · SCHEDULE 13D/A (0001193125-26-323654): SCHEDULE 13D/A - AI Biotechnology LLC — *Yarrow Bioscience, Inc. (formerly VYNE Therapeutics Inc.) is a pharmaceutical preparations company.* On July 27, 2026, Yellow Merger Sub Corp., a wholly owned subsidiary of VYNE Therapeutics Inc., merged with and into Yarrow Bioscience, Inc. (Pre-Merger Yarrow), with Pre-Merger Yarrow continuing as a wholly owned subsidiary of VYNE Therapeutics Inc. and serving as the surviving corporation. In connection with the merger's completion, VYNE Therapeutics Inc. changed its name to Yarrow Bioscience, Inc. Prior to the merger, the company effected a 1-for-50 reverse stock split effective July 24, 2026, under which every 50 shares of Common Stock were automatically combined into one share. As a result of the reverse stock split, AI Biotechnology's 1,116,585 shares were combined into 22,331 whole shares, and the Warrants held by AI Biotechnology were adjusted from 7,792,448 shares to 155,849 shares issuable upon exercise.
  https://www.sec.gov/Archives/edgar/data/1942670/0001193125-26-323654.txt

## Citations
- 0001193125-26-323654 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526323654